In Type II EOC, the “hot” immunophenotype of OC, particularly HGSC, IL6 is aggressively involved in driving immune evasion and tumor progression, such as upregulating immune checkpoint molecules, including PD1 and CTLA4. This evidence concerns the gene IL6 and neoplasm.